about
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyEffect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysisProposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemPrognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature.Cytogenetic risk stratification in chronic myelomonocytic leukemia.Revised international prognostic scoring system for myelodysplastic syndromes.Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysisReproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy.Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas.Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes.Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.A Lot to Learn about Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia.Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation.Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia.Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donorsPrognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromesSimultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survivalInfluence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow TransKIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemiaA broken cord blood bag: placing the unit in a sterile zip-lock bag before thawing prevents catastrophic eventsClinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaUnrelated cord blood transplants in adults with hematologic malignanciesSevere Infections after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Comparison of Cord Blood Transplantation with Peripheral Blood and Bone Marrow TransplantationThe JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrowThe JAK2 V617F mutation is rare in RARS but common in RARS-T
P50
Q24563021-0A8B21BA-B63A-4A2A-A462-135F9C95071DQ30424777-CB18AAAE-D517-4819-8C19-D25F556DDEECQ33380307-9DF10DA7-D390-4D9A-B30E-DBAE384A0CB9Q33395648-7DCCA851-7DBB-4353-ADCB-EDB4CD3F5879Q33727686-EE48990A-42BF-4F70-BF29-D69F99502661Q34612592-FABFECD7-8C69-40B0-A1F3-F607519CEB41Q34639717-069C7743-2356-4CA9-944A-6853A2E7EE01Q35185685-B39B3007-24CD-4B97-A76F-C5DDA16FC664Q36862492-9CE67154-C5BC-4FE7-9301-7EAAE0288B39Q37429693-084E0711-D1A5-4A20-B8E2-ED5599C0EB29Q37552083-3B31B63D-4333-423A-B333-6150693F7750Q37723835-CC0DB67B-4F15-4035-BA3E-E95CF40907ADQ37870316-8222E594-9BAD-4D63-9B49-0E2CAC615A38Q38107912-3F4AB2BE-EA3B-4933-B213-42EACDA58A84Q43289874-2F53136E-E169-4DDE-A625-A9C0AA9BF98CQ43706937-EF960970-B2DD-4973-A93D-D3343A1C4880Q43770648-88FA7866-83F6-44C0-B3B3-6D01D8BF2D1EQ44117655-784E1A41-FBD7-4FE0-8A02-09817A5DB6DBQ47677785-E97128E1-0BF8-48C8-B41D-637478C21D8EQ47860858-23D94A98-9476-4C0A-94B7-3F23EAEB4F4EQ50213662-D963C38A-EEA6-49F4-982D-A4EB85D14546Q51735716-BE3D8CF2-3960-4744-8299-58ED50B26812Q51798158-CACC15B8-EB2B-433F-8756-B905581CFC7FQ51961297-3E5AEED7-DED9-48C9-915B-EB56E1D2E0D4Q53101662-921F83BA-41A3-492D-9904-6DCFAA9027ADQ53267488-66A03EAF-5EA6-4172-A4B8-3C9CCD362062Q53469016-D14291CD-E856-4883-B046-A2F34CC4D6E1Q53752632-9706D14C-0B9E-4159-A5D3-4908046E4B7DQ53878426-C42443EB-EB8D-42A9-BE8D-3B3F42095EB4Q56898336-25386D48-8D34-4EA2-9260-E3B503E286FEQ58010106-36B82A4A-92DC-4616-AE64-128DB01B43B4Q58865825-CFF88B1A-5AD9-422E-828B-A47CF698FC94Q58865851-D1C7DC33-1B88-4CAA-B9F6-8CE5D75103B5Q58865885-25404213-0C93-4457-AC73-293175CC0EFAQ58865920-60D16375-79D1-4471-AEAD-E7EFF2CFDDCEQ58865927-68499471-2C2F-4BAE-B732-E034803776ACQ58865929-4121AE38-20B8-4D1C-9310-014FE913A901Q58865930-81FE3743-8724-4937-8606-5583B2AC21E1Q58865932-16C4B5CE-7B9A-497D-9BAA-6BA2D2E9F958Q58865933-7D5337BB-8A8F-4428-B9B1-7F8C3F97F17D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Guillermo F Sanz
@ast
Guillermo F Sanz
@en
Guillermo F Sanz
@es
Guillermo F Sanz
@nl
type
label
Guillermo F Sanz
@ast
Guillermo F Sanz
@en
Guillermo F Sanz
@es
Guillermo F Sanz
@nl
prefLabel
Guillermo F Sanz
@ast
Guillermo F Sanz
@en
Guillermo F Sanz
@es
Guillermo F Sanz
@nl
P106
P1153
35375448700
P21
P31
P496
0000-0002-2767-8191